Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023889171> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W3023889171 endingPage "113353" @default.
- W3023889171 startingPage "113353" @default.
- W3023889171 abstract "Abstract Ivosidenib, as an oral mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, was awarded approval in the USA for the targeted therapy of relapsed or refractory acute myeloid leukemia (AML) in adult patients, who also had a susceptible enzyme to mIDH1. The aim of our present study was to develop and validate an accurate and fast assay based on the ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) technique for the quantification of ivosidenib in plasma and to investigate the possible effects of different CYP3A4 inhibitors (voriconazole, itraconazole and fluconazole) on ivosidenib metabolism in rats. After the fast protein crash with acetonitrile, chromatographic separation of ivosidenib and erlotinib (used as the internal standard in this experiment, IS) was accomplished using an Acquity BEH C18 (2.1 mm × 50 mm, 1.7 μm) column, and detection of the analyte was also performed using a Xevo TQ-S triple quadrupole tandem mass spectrometer in the positive ion electrospray ionization (ESI) interface. The assay showed enough linearity over a 0.5−6000 ng/mL calibration range. The application of the validated bioanalytical method based on the UHPLC-MS/MS technique was further successfully exhibited in an animal study of the drug-drug interaction between ivosidenib (50 mg/kg) and voriconazole (20 mg/kg)/itraconazole (20 mg/kg)/fluconazole (20 mg/kg) in rats. Voriconazole, itraconazole and fluconazole increased the exposure of ivosidenib in plasma by different degrees and also had a potential inhibitory effect on the metabolism of ivosidenib. Thus, a dose reduction or interruption of ivosidenib may be important to guide the practice of clinical medicine." @default.
- W3023889171 created "2020-05-13" @default.
- W3023889171 creator A5002627636 @default.
- W3023889171 creator A5007123441 @default.
- W3023889171 creator A5011298090 @default.
- W3023889171 creator A5032984913 @default.
- W3023889171 creator A5055493445 @default.
- W3023889171 date "2020-08-01" @default.
- W3023889171 modified "2023-10-18" @default.
- W3023889171 title "Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS" @default.
- W3023889171 cites W1847894796 @default.
- W3023889171 cites W1995675594 @default.
- W3023889171 cites W2106509831 @default.
- W3023889171 cites W2134061682 @default.
- W3023889171 cites W2321413400 @default.
- W3023889171 cites W2592164001 @default.
- W3023889171 cites W2767704967 @default.
- W3023889171 cites W2806682325 @default.
- W3023889171 cites W2890413816 @default.
- W3023889171 cites W2913972861 @default.
- W3023889171 cites W2919003988 @default.
- W3023889171 cites W2941606588 @default.
- W3023889171 cites W2942027709 @default.
- W3023889171 cites W2959525851 @default.
- W3023889171 doi "https://doi.org/10.1016/j.jpba.2020.113353" @default.
- W3023889171 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32417565" @default.
- W3023889171 hasPublicationYear "2020" @default.
- W3023889171 type Work @default.
- W3023889171 sameAs 3023889171 @default.
- W3023889171 citedByCount "8" @default.
- W3023889171 countsByYear W30238891712020 @default.
- W3023889171 countsByYear W30238891712021 @default.
- W3023889171 countsByYear W30238891712022 @default.
- W3023889171 countsByYear W30238891712023 @default.
- W3023889171 crossrefType "journal-article" @default.
- W3023889171 hasAuthorship W3023889171A5002627636 @default.
- W3023889171 hasAuthorship W3023889171A5007123441 @default.
- W3023889171 hasAuthorship W3023889171A5011298090 @default.
- W3023889171 hasAuthorship W3023889171A5032984913 @default.
- W3023889171 hasAuthorship W3023889171A5055493445 @default.
- W3023889171 hasConcept C112705442 @default.
- W3023889171 hasConcept C185592680 @default.
- W3023889171 hasConcept C2777071850 @default.
- W3023889171 hasConcept C2779548794 @default.
- W3023889171 hasConcept C2780651595 @default.
- W3023889171 hasConcept C2780690907 @default.
- W3023889171 hasConcept C43617362 @default.
- W3023889171 hasConcept C71924100 @default.
- W3023889171 hasConcept C86803240 @default.
- W3023889171 hasConcept C89423630 @default.
- W3023889171 hasConcept C98274493 @default.
- W3023889171 hasConceptScore W3023889171C112705442 @default.
- W3023889171 hasConceptScore W3023889171C185592680 @default.
- W3023889171 hasConceptScore W3023889171C2777071850 @default.
- W3023889171 hasConceptScore W3023889171C2779548794 @default.
- W3023889171 hasConceptScore W3023889171C2780651595 @default.
- W3023889171 hasConceptScore W3023889171C2780690907 @default.
- W3023889171 hasConceptScore W3023889171C43617362 @default.
- W3023889171 hasConceptScore W3023889171C71924100 @default.
- W3023889171 hasConceptScore W3023889171C86803240 @default.
- W3023889171 hasConceptScore W3023889171C89423630 @default.
- W3023889171 hasConceptScore W3023889171C98274493 @default.
- W3023889171 hasFunder F4320332531 @default.
- W3023889171 hasLocation W30238891711 @default.
- W3023889171 hasOpenAccess W3023889171 @default.
- W3023889171 hasPrimaryLocation W30238891711 @default.
- W3023889171 hasRelatedWork W1965349779 @default.
- W3023889171 hasRelatedWork W1985758966 @default.
- W3023889171 hasRelatedWork W2064628661 @default.
- W3023889171 hasRelatedWork W2091932747 @default.
- W3023889171 hasRelatedWork W2338395605 @default.
- W3023889171 hasRelatedWork W2352972675 @default.
- W3023889171 hasRelatedWork W2907967108 @default.
- W3023889171 hasRelatedWork W2952801121 @default.
- W3023889171 hasRelatedWork W3085943042 @default.
- W3023889171 hasRelatedWork W38472955 @default.
- W3023889171 hasVolume "187" @default.
- W3023889171 isParatext "false" @default.
- W3023889171 isRetracted "false" @default.
- W3023889171 magId "3023889171" @default.
- W3023889171 workType "article" @default.